A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Running, not enrolling · Phase 1

Conditions studied: Metastatic Breast Cancer

In brief

DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer

Key facts

Study ID

NCT04556773

Run by

AstraZeneca

People needed

138

Starts

2020-12-17

Expected to finish

2027-06-01

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Commack, New York, United States
• Research Site — Harrison, New York, United States
• Research Site — New York, New York, United States
• Research Site — New York, New York, United States
• Research Site — Uniondale, New York, United States
• Research Site — Chapel Hill, North Carolina, United States
• Research Site — Chattanooga, Tennessee, United States
• Research Site — Germantown, Tennessee, United States
• Research Site — Fort Worth, Texas, United States
• Research Site — Melbourne, Australia
• Research Site — Westmead, Australia
• Research Site — Edegem, Belgium
• Research Site — Leuven, Belgium
• Research Site — Ottignies, Belgium
• Research Site — Goiânia, Brazil
• Research Site — Porto Alegre, Brazil
• Research Site — Porto Alegre, Brazil
• Research Site — São Paulo, Brazil
• Research Site — São Paulo, Brazil
• Research Site — Kelowna, British Columbia, Canada
• Research Site — Québec, Quebec, Canada
• Research Site — Villejuif, France
• Research Site — Monterrey, Mexico
• Research Site — Moscow, Russia
• Research Site — Moscow, Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.